Nigel Baker

3.2k total citations
24 papers, 1.2k citations indexed

About

Nigel Baker is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Nigel Baker has authored 24 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Hematology and 6 papers in Molecular Biology. Recurrent topics in Nigel Baker's work include Erythropoietin and Anemia Treatment (4 papers), Neutropenia and Cancer Infections (3 papers) and Hematopoietic Stem Cell Transplantation (3 papers). Nigel Baker is often cited by papers focused on Erythropoietin and Anemia Treatment (4 papers), Neutropenia and Cancer Infections (3 papers) and Hematopoietic Stem Cell Transplantation (3 papers). Nigel Baker collaborates with scholars based in United Kingdom, United States and Switzerland. Nigel Baker's co-authors include Dylan Rosser, Piotr Ponikowski, Scott M. Wasserman, Peter G. Kerr, Dirk J. van Veldhuisen, John G.F. Cleland, Peter Bárány, Johannes F.E. Mann, Janet M Wilson and Kenneth Dickstein and has published in prestigious journals such as Journal of Clinical Oncology, Journal of the American College of Cardiology and Kidney International.

In The Last Decade

Nigel Baker

24 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nigel Baker United Kingdom 13 470 337 251 250 173 24 1.2k
Ulrike M. Reiss United States 19 552 1.2× 267 0.8× 111 0.4× 453 1.8× 215 1.2× 56 1.7k
B Viron France 12 400 0.9× 149 0.4× 300 1.2× 317 1.3× 156 0.9× 40 1.4k
Manish J. Gandhi United States 23 471 1.0× 128 0.4× 79 0.3× 186 0.7× 192 1.1× 82 1.4k
Stanley E. Gräber United States 18 1.1k 2.4× 151 0.4× 338 1.3× 226 0.9× 116 0.7× 42 1.7k
Weihong Zhao China 22 101 0.2× 167 0.5× 378 1.5× 521 2.1× 213 1.2× 84 1.7k
Leo J. McCarthy United States 16 501 1.1× 99 0.3× 132 0.5× 79 0.3× 155 0.9× 46 1.3k
Nicholas Bandarenko United States 19 616 1.3× 123 0.4× 299 1.2× 106 0.4× 191 1.1× 36 1.9k
Seth A. Rudnick United States 15 664 1.4× 302 0.9× 46 0.2× 132 0.5× 172 1.0× 23 1.3k
Kazunori Murata United States 15 190 0.4× 108 0.3× 152 0.6× 141 0.6× 75 0.4× 31 828
B. Gail Macik United States 19 947 2.0× 101 0.3× 60 0.2× 140 0.6× 178 1.0× 32 1.9k

Countries citing papers authored by Nigel Baker

Since Specialization
Citations

This map shows the geographic impact of Nigel Baker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nigel Baker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nigel Baker more than expected).

Fields of papers citing papers by Nigel Baker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nigel Baker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nigel Baker. The network helps show where Nigel Baker may publish in the future.

Co-authorship network of co-authors of Nigel Baker

This figure shows the co-authorship network connecting the top 25 collaborators of Nigel Baker. A scholar is included among the top collaborators of Nigel Baker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nigel Baker. Nigel Baker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Rolfo, Christian, Judith de Vos‐Geelen, Nicolás Isambert, et al.. (2017). PHARMACOKINETICS AND SAFETY OF OLAPARIB IN PATIENTS WITH ADVANCED SOLID TUMORS AND HEPATIC OR RENAL IMPAIRMENT. Clinical Pharmacology & Therapeutics. 101. 1 indexed citations
3.
Domchek, Susan M., Yung‐Jue Bang, George Coukos, et al.. (2016). MEDIOLA: A phase I/II, open-label trial of olaparib in combination with durvalumab (MEDI4736) in patients (pts) with advanced solid tumours. Annals of Oncology. 27. vi377–vi377. 6 indexed citations
4.
5.
Tabernero, Josep, Sant P. Chawla, Hedy L. Kindler, et al.. (2014). Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab. Targeted Oncology. 10(1). 65–76. 25 indexed citations
6.
7.
Lane, P. W., Julian P. T. Higgins, Betsy Anagnostelis, et al.. (2013). Methodological quality of meta‐analyses: matched‐pairs comparison over time and between industry‐sponsored and academic‐sponsored reports. Research Synthesis Methods. 4(4). 342–350. 10 indexed citations
8.
Higgins, Julian P. T., P. W. Lane, Betsy Anagnostelis, et al.. (2013). A tool to assess the quality of a meta‐analysis. Research Synthesis Methods. 4(4). 351–366. 59 indexed citations
9.
Cohn, Allen Lee, Josep Tabernero, Joan Maurel, et al.. (2012). Conatumumab (CON) plus FOLFIRI (F) or ganitumab (GAN) plus F for second-line treatment of mutant (MT) KRAS metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 30(4_suppl). 534–534. 3 indexed citations
10.
Willis, F., Penella J. Woll, Davinder S. Theti, et al.. (2009). Pegfilgrastim for peripheral CD34+ mobilization in patients with solid tumours. Bone Marrow Transplantation. 43(12). 927–934. 12 indexed citations
11.
12.
Malluche, Hartmut H., Marie-Claude Monier-Faugere, Chaim Charytan, et al.. (2008). An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clinical Nephrology. 69(4). 269–278. 92 indexed citations
13.
Russell, NH, Rolf M. Mesters, J. Schubert, et al.. (2008). A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. Haematologica. 93(3). 405–412. 51 indexed citations
14.
Willis, F., et al.. (2008). Pegfilgrastim successfully mobilizes megakaryocyte progenitors into the peripheral blood in subjects with solid tumours. Bone Marrow Transplantation. 42(3). 167–173. 1 indexed citations
15.
Ponikowski, Piotr, Stefan D. Anker, Joanna Szachniewicz, et al.. (2007). Effect of Darbepoetin Alfa on Exercise Tolerance in Anemic Patients With Symptomatic Chronic Heart Failure. Journal of the American College of Cardiology. 49(7). 753–762. 164 indexed citations
16.
Veldhuisen, Dirk J. van, Kenneth Dickstein, A Cohen-Solal, et al.. (2007). Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. European Heart Journal. 28(18). 2208–2216. 162 indexed citations
17.
Baker, Nigel, et al.. (2006). Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa on hemoglobin response and symptoms in patients with heart failure and anemia. Data Archiving and Networked Services (DANS). 7 indexed citations
18.
Weizman, Abraham, Marc Klapholz, Inder S. Anand, et al.. (2006). 548 The effect of darbepoetin alfa treatment on clinical outcomes in anemic patients with symptomatic heart failure: a preplanned pooled analysis of two randomized, double-blind, placebo-controlled trials. European Journal of Heart Failure Supplements. 5(1). 121–121. 7 indexed citations
19.
Suranyi, Michael, John Cunningham, Piergiorgio Messa, et al.. (2003). Oral cinacalcet HCI (AMG 073) for the treatment of hemodialysis patients with secondary hyperparathyroidism (HPT): Results of a European/Australian-Phase 3 study. Journal of the American Society of Nephrology. 14. 10 indexed citations
20.
Vanrenterghem, Yves, Peter Bárány, Johannes F.E. Mann, et al.. (2002). Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney International. 62(6). 2167–2175. 129 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ulrike M. Reiss Breakdown of academic impact, for papers by B Viron Breakdown of academic impact, for papers by Manish J. Gandhi Breakdown of academic impact, for papers by Stanley E. Gräber Breakdown of academic impact, for papers by Weihong Zhao Breakdown of academic impact, for papers by Leo J. McCarthy Breakdown of academic impact, for papers by Nicholas Bandarenko Breakdown of academic impact, for papers by Seth A. Rudnick Breakdown of academic impact, for papers by Kazunori Murata Breakdown of academic impact, for papers by B. Gail Macik
Rankless by CCL
2026